Eli Lilly Reports P-III Trial (SURMOUNT-2) Results of Tirzepatide for Obesity or Overweight and Type 2 Diabetes
- The P-III trial evaluating tirzepatide (10 & 15mg) vs PBO in a ratio (1:1:1) in 938 patients with obesity or overweight & T2D across the US, Argentina, Brazil, India, Japan, Puerto Rico, Russia & Taiwan
- The trial met co-primary objectives i.e., patients achieved avg. weight reductions of 13.4% on 10mg & 15.7% on 15mg; 81.6% & 86.4% vs 30.5% achieved 5% body weight reduction for the efficacy estimand
- The trial also met secondary objectives incl. reduction in A1C & other cardiometabolic parameters, 41.4% & 51.8% vs 2.6% achieved 15% body weight reduction, reduction in A1C was similar to the (SURPASS) trials, mean baseline body weight & baseline A1C of 8.0%. The overall safety profile was similar to prior reported trials & to incretin-based therapies
Ref: PRNewswire | Image: Eli Lilly
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.